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Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine
in metastatic melanoma
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T McCalmont1 and AI Daud*,1
1University of California, San Francisco, MTZ-A741, 1600 Divisadero Street, San Francisco, CA 94143, USA; 2H Lee Moff itt Cancer Center, Tampa,
FL, USA
BACKGROUND: Src inhibitors sensitise melanoma cells to chemotherapy in preclinical models. The combination of dasatinib and
dacarbazine was tested in a phase I trial in melanoma.
METHODS: Patients had ECOG performance status 0–2 and normal organ function. Dacarbazine was administered on day 1 and
dasatinib on day 2 through 19 of each 21-day cycle. Both were escalated from 50mg b.i.d. of dasatinib and 800mgm2 of
dacarbazine. Available pre-treatment biopsies were sequenced for BRAF, NRAS, and C-Kit mutations.
RESULTS: Dose-limiting toxicity was reached at dasatinib 70mg b.i.d./dacarbazine 1000mgm2, and was predominantly
haematological. In 29 patients receiving dasatinib 70mg b.i.d., the objective response rate (ORR) was 13.8%, the clinical benefit
rate (ORRþ SD) was 72.4%, the 6-month progression-free survival (PFS) was 20.7%, and the 12-month overall survival (OS) was
34.5%. Two out of three patients who were wild type for BRAF, NRAS, and c-KIT mutations had confirmed partial responses, and
one had a minor response.
CONCLUSION: The recommended phase II dose is dasatinib70mg b.i.d with dacarbazine 800mgm2. PFS and OS data for dasatinib at
70mg b.i.d. with dacarbazine compared favourably with historical controls. Preliminary data support evaluating tumour mutation
status further as a biomarker of response.
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The incidence of melanoma is increasing rapidly worldwide. In the
United States, an estimated 8700 deaths (Jemal et al, 2010) result
annually from this disease. The development of metastatic disease
is associated with a dismal prognosis (Barth et al, 1995) and, until
recently, the FDA-approved therapeutic options were not asso-
ciated with a survival benefit (Atkins et al, 1999, 2000; Chapman
et al, 2011). Ipilimumab, an anti-CTLA-4 antibody, does confer a
modest survival benefit in this population, but survival is still
limited (median overall survival (OS)¼ 10–11.2 months; Hodi
et al, 2010; Robert et al, 2011). Therapeutic strategies targeting
tumour-driving oncogenes now promise to revolutionise the
treatment of melanoma. In particular, the BRAF inhibitors
vemurafenib and GSK2118643 show evidence of clinical activity
in a large proportion of patients whose tumours harbour
BRAFV600E/K mutations (Flaherty et al, 2010; Kefford et al, 2010;
Chapman et al, 2011). However, about half of the cutaneous
melanoma tumours do not harbour BRAF mutations, and even in
patients with these mutations, responses to vemurafenib are
transient, lasting a median of 6.7 months (Chapman et al, 2011).
Therefore, the identification of additional therapeutic targets in
melanoma is urgently needed.
Given the role of invasion and metastasis in the clinical
progression of melanoma, strategies inhibiting these processes
could substantially impact the clinical course of the disease.
Src and the related Src family kinases signal through multiple
downstream intermediaries including STAT3 (Yu et al, 1995),
FAK, and b-catenin (Irby et al, 2005), and Src activation has been
implicated in decreased tumour cell adhesion, increased invasive-
ness, and increased motility (Buettner et al, 2008). Src activation
has been implicated in the pathogenesis of colon (Irby et al, 1999;
Kline et al, 2008), lung (Song et al, 2006), pancreas (Trevino et al,
2006), breast (Hiscox et al, 2006; Jallal et al, 2007; Morgan et al,
2009), and prostate cancer (Nam et al, 2005; Kotha et al, 2006). In
uveal melanoma, Src activation has been associated with the MAP
kinase pathway activation (Maat et al, 2009). Src is also frequently
activated in cutaneous melanoma (Niu et al, 2002; Homsi et al,
2009; Eustace et al, 2010), and Src overexpression increases
cutaneous melanoma cell proliferation and decreases adhesion
(Boukerche et al, 2010). Conversely, Src inhibition leads to
decreased proliferation and migration in melanoma cell lines
(Eustace et al, 2008, 2010).
Dasatinib is a multi-targeted small-molecule kinase inhibitor
that inhibits Src and c-Kit in low nanomolar range. C-Kit is
mutated in approximately 15–20% of acral and mucosal mela-
nomas (Beadling et al, 2008; Satzger et al, 2008; Torres-Cabala
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et al, 2009), and marked objective tumour responses have been
observed in patients with exon 11 and exon 13 c-Kit mutant
melanoma treated with dasatinib. In one case, this occurred even
after disease progression on imatinib (Woodman et al, 2009).
In melanoma cell lines that have not been selected for c-Kit
mutations, dasatinib decreases cellular proliferation (Eustace et al,
2010) and enhances apoptosis (Niu et al, 2002), and dasatinib
decreases cell migration even in cells in which it has no anti-
proliferative effect (Eustace et al, 2008, 2010). Dasatinib may also
inhibit the formation of new melanoma lung metastases in vivo
(Fraser et al, 2010). Dasatinib monotherapy is only modestly active
in melanoma patients unselected for c-Kit mutations. In a phase II
clinical trial, 36 metastatic melanoma patients were treated with
dasatinib dosed at 70–100mg PO b.i.d. Two partial responses were
reported and the 6-month progression-free survival (PFS) rate was
13% (Kluger et al, 2011). One responding patient had a confirmed
c-Kit mutation in exon 13; the other was a c-KIT wild type. Four
c-KIT wild-type patients were described with prolonged stabilisa-
tion of disease lasting up to 136 weeks. Common dose-limiting
toxicities associated with dasatinib in this trial included pleural
effusions, dyspnoea, fatigue, and diarrhoea.
In addition to its single agent activity, cell-culture experiments
have demonstrated an antiproliferative synergy between dasatinib
and chemotherapeutic agents including cisplatin (Homsi et al,
2009) and temozolomide (Eustace et al, 2008) in c-Kit wild-type
melanoma. Dacarbazine is a commonly employed alkylating agent
with single-agent activity in advanced melanoma (Luikart et al,
1984; Chapman et al, 1999; Middleton et al, 2000; Schadendorf
et al, 2006). We conducted a phase I clinical trial of dasatinib in
combination with dacarbazine, to determine the safety and toler-
ability of this regimen in patients with advanced melanoma and
to identify a recommended phase II dose. Selective dose expan-
sion cohorts were evaluated for preliminary evidence of efficacy.
Tumours from a subset of patients were also evaluated for BRAF,
NRAS, and c-Kit mutations as a potential biomarker of response.
MATERIALS AND METHODS
Study design
This study was initially designed as a two-part study, with dose-
escalation and dose-expansion cohorts. The first three of these cohorts
included twice-daily dosing of dasatinib, and the remaining two cohorts
included once-daily dosing. The dose escalation for the twice-daily
dasatinib dosing schedule was based on a standard phase I dose escala-
tion (3þ 3) scheme (Ratain et al, 1993). Dose expansion was eventually
carried out in multiple cohorts for evaluation of dose-limiting toxicity
(DLT) events and for better estimation of efficacy and toxicity. A total
of five cohorts were evaluated to identify the maximum tolerated dose
(MTD) of dacarbazine in combination with dasatinib (Bristol-Myers
Squibb, New York, NY, USA). Dosing was as follows: cohort 1,
dasatinib 50mg PO b.i.d, dacarbazine 800mgm2; cohort 2, dasatinib
70mg PO b.i.d, dacarbazine 800mgm2; cohort 3, dasatinib 70mg PO
b.i.d, dacarbazine 1000mgm2; cohort 4, dasatinib 140mg PO daily,
dacarbazine 1000mgm2; and cohort 5, dasatinib 100mg PO daily,
dacarbazine 1000mgm2. Written informed consent was obtained
from all patients before the initiation of pre-treatment screening
procedures. The Scientific Review Committees and the Institu-
tional Review Boards at the Moffitt Cancer Center in Tampa,
FL, USA, and at the University of California, San Francisco, CA,
USA, approved the trial. Accrual began in January 2008 and was
completed in August 2009.
Patients
Eligible patients had unresectable stage III or stage IV melanoma.
Patients were required to have measurable or evaluable disease,
and prior treatment with dacarbazine or temozolomide was not
allowed. All patients were required to have an ECOG performance
status of 0–2, adequate bone marrow function (absolute neutro-
phil count 41.5 109 l1, haemoglobin 49 g dl1, platelets
4100 109 l1), renalfunction (creatinine o1.5 times the upper
limit of normal), and hepatic function (total bilirubin o1.5 times
the upper limit of normal, AST and ALT o2.5 times the upper
limit of normal). Patients with vascular events within 6 months
were excluded, as were patients with QTc prolongation (4470ms)
and ongoing cardiac dysrhythmias. Patients with leptomeningeal
disease were excluded, but neurologically intact patients with
treated brain metastasis that had no evidence of recurrence for at
least 12 weeks were eligible.
Study treatment
All patients were treated with dacarbazine on day 1 of each 21-day
cycle, and dasatinib was taken orally on treatment days 2 through
19. Dasatinib was not given on treatment days 20, 21, and 1, due to
concern that it could decrease cellular proliferation and diminish
the efficacy of cytotoxic chemotherapy. Concurrent use of potent
CYP3A4 inhibitors or of medications known to prolong the QT
interval was prohibited. Before each dacarbazine infusion, patients
were pre-medicated with dexamethasone, ondansetron, and
lorazepam. Treatment was continued until disease progression,
withdrawal of consent, or the development of unacceptable
treatment-related toxicity.
Toxicity assessment
Pre-treatment assessments included a complete history and
physical examination, laboratories including a complete blood
count, a comprehensive metabolic panel, and a 12-lead electro-
cardiogram. Adverse events were graded using the Common
Terminology Criteria for Adverse Events version 3.0 at weekly
follow-up visits during the first 21-day treatment cycle, and every
three weeks thereafter. Dose-limiting toxicities were defined as any
grade 4 haematological toxicity (except asymptomatic grade 4
neutropenia lasting 7 days or less); prolonged grade 3 or 4
thrombocytopenia (47 days) or thrombocytopenia associated
with bleeding, requiring platelet transfusion; any grade 3 or 4 non-
haematological toxicity, despite optimal supportive care; and any
toxicity considered unacceptable by the study principal investi-
gator. The MTD was initially defined as the highest dose level at
which fewer than two out of six patients (o33%) experienced a
DLT in cycle 1, but post-DLT period events were ultimately taken
into consideration for defining the MTD. After the 21-day DLT
period, dose modifications were made for febrile neutropenia
(T438.51, ANC o1000mm3); grade 3 or 4 thrombocytopenia,
persistent neutropenia (ANC o1000mm3) or thrombocytopenia
(platelet count o100 000 ml1) on day 1 of any treatment cycle;
grade 2 or higher liver function abnormalities; diarrhoea; and any
other grade 3 or higher non-haematological toxicity other than
fever, chills, and flu-like symptoms.
Response assessment
Planned secondary endpoints included overall response rate
(ORR) by the Response Evaluation Criteria in Solid Tumours
(RECIST v1.0), OS and PFS. Patients receiving at least two cycles of
treatment and those taken off study, early for clinical disease
progression were considered evaluable for response. Tumour
assessments were made at baseline and at the end of every second
cycle (i.e. every 6 weeks). Partial and complete responses were
defined by the best treatment response achieved. Stable disease
was defined as maintenance of the sum of lesions diameters
between a 30% reduction and a 20% increase of overall tumour
size over 12 weeks or longer. Patients were assessed for adverse
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events on the basis of the clinical and laboratory data on treatment
days 1, 8, and 15 of the first 21-day cycle, then every 3 weeks on
day 1 of each subsequent cycle.
Statistics
Descriptive Kaplan–Meier survival analysis was performed and
subgroup survival comparisons using log-rank were performed
using SPSS version 17 (Chicago, IL, USA).
Exploratory biomarker analysis
A post-hoc analysis of tumour mutation status as a predictor of
response was performed on the 12 of 46 evaluable patients who
had tissue available for analysis. Available pre-treatment, formalin-
fixed, paraffin-embedded specimens were used to prepare 5-mm
sections. Sections were microdissected to minimise stromal
contamination and were genotyped using the PCR for known
oncogenic mutations in BRAF exon 15, NRAS exons 1 and 2, c-Kit
exons 9, 11, 13, 17, and 18, GNAQ exon 5, and GNA11 exon 5. The
two patients with tumours positive for BRAF mutations were
identified through screening for a subsequent clinical trial of the
BRAF inhibitor PLX-4032 (NCT00949702).
RESULTS
Patients and treatment
A total of 51 patients were consented and screened for this study.
One patient was found to be ineligible. Another patient entered the
study with a diagnosis of melanoma of the soft parts, a disease that
is now considered a sarcoma subtype. The patient was included in
toxicity, but not response assessments. A total of 49 patients with
melanoma, who received any treatment on study, were also
considered evaluable for toxicity. Another 46 patients were
considered to be evaluable for response. Two inevaluable
melanoma patients did not complete two cycles of therapy due
to toxicity (N¼ 2), and one withdrew consent (N¼ 1) and did not
have restaging scans. Complete patient demographics are listed in
Table 1.
Toxicity and DLTs
The most common grade 3 and 4 adverse events were haemato-
logical (50% of patients overall), including neutropenia, anaemia,
and thrombocytopenia (Tables 2 and 3). No DLTs were observed
in cohorts 1 and 2. One of the first three patients in cohort 3
(dacarbazine 1000mgm2, dasatinib 70mg PO b.i.d) developed
dose-limiting thrombocytopenia, and the cohort was expanded to
6 and then to 14 patients to gain additional information regarding
treatment-associated toxicity. The sample sizes for cohort expan-
sions were based on the observation of latent (post-DLT period)
toxicities rather than pre-planned statistical considerations. Two
additional patients in the expansion of cohort 3 developed dose-
limiting febrile neutropenia. After the DLT period, one patient
developed refractory grade 3 diarrhoea, and another patient had a
myocardial infarction that was considered possibly related to
treatment. The latent toxicities observed in expansion cohort 3
precluded further clinical development at these dose levels, and
dacarbazine 800mgm2 with dasatinib 70mg PO b.i.d was
designated as the MTD for twice-daily dosing of dasatinib. Cohort
2 was subsequently expanded to a total of 19 patients. This
regimen was generally well tolerated, with 9 of 19 patients (47%)
experiencing non-dose-limiting (generally transient) grade 3 and 4
haematological adverse events. Grade 3 and 4 non-hematologic
adverse events were limited to one patient with grade 3 dyspnoea,
two patients with grade 3 hyponatraemia, and one patient with
grade 3 hyperglycaemia.
Two regimens with once-daily dasatinib dosing were also
evaluated. One out of three patients in cohort 4 (dacarbazine
1000mgm2 with dasatinib 140mg PO daily) developed dose-
limiting grade 3 thrombocytopenia and grade 3 dyspnoea during
the DLT period, and a second patient developed grade 3 dyspnoea
on cycle 2 day 15. On the basis of these events, dacarbazine
1000mgm2 with dasatinib 140mg PO daily was thought to be too
toxic for further development. There were no DLTs in a total of
11 patients treated in cohort 5 (dacarbazine 1000mgm2 with
dasatinib 100mg PO daily). Five patients in this cohort had non-
dose-limiting grade 3 and 4 haematological toxicities, one patient
developed grade 3 fatigue, and one patient had an episode of grade
3 gastrointestinal bleeding that was probably treatment related.
Further expansion of cohort 5 was not pursued due to the failure of
once-daily dasatinib dosing to induce objective tumour responses
in these 11 patients.
Response and survival
A total of 4 out of 29 evaluable patients (13.8%) receiving dasatinib
70mg PO b.i.d. had partial responses by RECIST (Table 4), and 17
patients had stabilisation of disease for a clinical benefit rate
(ORRþ SD) of 72.4%. There were no objective responses in the
other three cohorts. Prolonged stabilisation of disease was
observed in all cohorts and in 26 out of 46 patients (56.5%)
overall. Clinical benefit (PRþ SD) was observed in 30 of 46
patients (65.2%). The median PFS in all patients was 13.4 weeks
and the median OS was 40.6 weeks. The median PFS in cohorts
Table 1 Patient demographics
Patient demographics (N¼ 50)
Age (years) 62.3±12.1
Gender
Male (%) 31 (62)
Female (%) 19 (38)
Stage
M1a (%) 6 (12)
M1b (%) 13 (26)
M1c (%) 31 (62)
Prior treatment
Chemotherapy (%) 2 (4)
Vaccine (%) 1 (2)
None (%) 47 (94)
Baseline lactate dehydrogenase
Normal (%) 32 (64)
Elevated (%) 18 (36)
ECOG performance status
0 (%) 23 (46)
1 (%) 22 (46)
2 (%) 2 (4)a
Primary site
Cutaneous
Torso (%) 13 (26)
Head and neck (%) 11 (22)
Extremity (%) 11 (22)
Multiple (%) 2 (4)
Unknown (%) 4 (8)
Ocular (%) 6 (12)
Mucosal (%) 2 (4)
Soft parts (%) 1b (2)
aECOG performance status was not documented for two patients. bPatient with
melanoma of the soft parts included in toxicity, but not response assessments.
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1–5 was 5.1, 14.0, 13.4, 12.0, and 11.6 weeks, respectively. The
median OS in cohorts 1–5 was 63.9, 40.6, 40.9, 28.6, and 40.9
weeks, respectively. In all, 3 out of 12 patients genotyped were
wild type for BRAF, NRAS, c-KIT, GNAQ, and GNA11 mutations.
Two of these patients had objective tumour responses and one had
a minor response (Figure 1). In patients receiving dasatinib 70mg
PO b.i.d., the 6-month PFS rate was 20.7% and the 12-month OS
rate was 34.5%.
Table 2 Toxicities possibly, probably, and definitely related to treatment
Dacarb/dasatinib Grade Heme GI Resp. Integ. Pain Constit. Lab Other
800/50 b.i.d. 1 and 2 Neutro (1)
Anaemia (2)
Platelets (1)
Nausea (2)
Diarrhoea (2)
Anorexia (2)
Dehydr (1)
Constip (1)
Alopecia (1) Headache (2) Fatigue (2) Low alb (2)
Low Na (1)
Low Ca (1)
Dizziness (1)
3 and 4
800/70 b.i.d. 1 and 2 Neutro (4)
Anaemia (14)
Platelets (11)
Anorexia (3)
Diarrhoea (8)
Nausea (13)
Constip (5)
Dysphagia (1)
Dysgeusia (1)
Anorexia (2)
Mucositis (1)
Effusion (1)
Dyspnea (2)
Oedema (1)
Rash (7)
Alopecia (2)
Flushing (3)
Headache (8)
Abdomen (1)
Myalgias (1)
Face (1)
Hand (1)
Fatigue (10)
Sweats (2)
Chills (3)
Insomnia (2)
Wt loss (1)
Fever (4)
High Mg (2)
Low Mg (2)
Low Ca (1)
High gluc (2)
Alk phos (5)
ALT (5)
AST (1)
Low alb (2)
Anxiety (1)
Oedema (5)
Numbness (2)
HSR (2)
Depress (1)
Polyuria (1)
Dizziness (1)
Neuropathy (1)
3 and 4 Neutro (6)
Anaemia (3)
Platelets (3)
Dyspnea (1) High gluc (1)
Low Na (1)
1000/70 b.i.d. 1 and 2 Neutro (2)
Anaemia (6)
Platelets (4)
Nausea (11)
Diarrhoea (7)
Er satiety (1)
Constip (1)
Anorexia (3)
Mucositis (1)
Tongue sw (1)
Effusions (3)
Atelect (1)
Cough (1)
Hiccups (1)
Dyspnea (1)
Rash (5)
Alopecia (3)
Pruritis (3)
Flushing (1)
Dry skin (1)
Foot (1)
Headache (4)
Myalgias (1)
Abdomen (2)
Fatigue (4)
Chills (2)
Fever (3)
Insomnia (1)
Low Ca (1)
Low K (1)
AST (1)
High gluc (1)
Long QT (5)
Tachycard (1)
Orthostasis (1)
Ging bleed (1)
Oedema (1)
3 and 4 Neutro (4)
Anaemia (4)
Platelets (7)
Diarrhoea (1) Oedema (1) Low Na (1) MI (1)
Neu fever (2)
1000/140 daily 1 and 2 Anaemia (3)
Platelets (2)
Dry mouth (1)
Nausea (2)
Constip (1)
Abd dist (1)
Anorexia (1)
Diarrhea (1)
Effusion (2) Rash (1) Headache (1)
Dysaesthesia (1)
Fatigue (3)
Chills (2)
Hot flash (1)
Wt loss (1)
Insomnia (1)
Sweats (1)
Alk phos (1)
Low Na (1)
Long QT (1)
Oedema (1)
Weakness (1)
3 and 4 Neutro (1)
Platelets (1)
Dyspnea (2)
1000/100 daily 1 and 2 Neutro (2)
Anaemia (3)
Platelets (3)
Nausea (6)
Anorexia (2)
Diarrhoea (2)
Dyspnea (1)
Cough (1)
Effusion (1)
Rash (4) Headache (2)
Abdomen (1)
Fatigue (6)
Fever (1)
Chills (1)
Alk phos (1)
ALT (2)
AST (1)
Epistaxis (1)
Oedema (2)
3 and 4 Neutro (5)
Platelets (1)
Fatigue (1) GI bleed (1)
Abbreviations: Abd dist¼ abdominal distention; Alb¼ albumin; Alk phos¼ alkaline phosphatase; ALT¼ alanine aminotransferase; AST¼ aspartate aminotransferase;
Constip¼ constipation; Constit.¼ constitutional; Dehydr¼ dehydration; GI¼ gastrointestinal; gluc¼ glucose; HSR¼ hypersensitivity reaction; Integ.¼ integument; MI¼myocardial
infarction; Neutro¼ neutropenia; QT¼QT interval in the electrocardiogram; Resp.¼ respiratory; Tongue sw¼ tongue swelling; Wt¼weight. Only the highest-grade toxicity for
each patient is reported. Grade 3 and 4 toxicities are noted in shaded regions. The number of events is in parentheses.
Table 3 Individual patient DLTs (during DLT period, cycle 1, day 1–21) and proportion of patients with any grade 3 and 4 toxicity, possibly, probably, and
definitely related to treatment
Patients with grade 3 or 4 toxicity by category (%)
Cohort
(dacarbazine/dasatinib)
DLT
category (N) DLT (%) Heme Pulm Card Bleed Infect GI Cons
1. 800/50 b.i.d. — 0 — — — — — — —
2. 800/70 b.i.d. — 0 9/19 (47) 1/19 (5) — — — — —
3. 1000/70 b.i.d. Heme (1)
NF (2)a
21.4 10/14 (71) 1/14 (7) 1/14 (7)b — 2/14 (14)c 1/14 (7)d —
4. 1000/140 q.d. Pulm (1)
Heme (1)
33 1/3 (33) 2/3 (67) — — — — —
5. 1000/100 q.d. — 0 5/11 (45) — — 1/11 (9)e — — 1/11 (9)f
Total 25/50 (50) 3/50 (6) 1/50 (2) 1/50 (2) 2/50 (4) 1/50 (2) 1/50 (2)
Abbreviations: Bleed¼ bleeding; Card¼ cardiac; Cons¼ constitutional; DLT¼ dose-limiting toxicity; GI¼ gastrointestinal; Heme¼ hematologic; Infect¼ infection; NF¼ neutropenic
fever; Pulm¼ pulmonary. aPatients in expansion cohort. bMyocardial infarction, possibly related. cFebrile neutropenia. dDiarrhoea. eGI bleeding in the setting of
thrombocytopenia. fFatigue.
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Additional subgroup analysis
There were no differences in PFS on the basis of gender, normal vs
elevated LDH, age, metastatic stage, or ocular vs non-ocular
primary. Median PFS by genotype was 5.7, 6, 17.3, and 34 weeks for
patients with BRAF (N¼ 2), NRAS (N¼ 4), GNAQ/GNA11 (N¼ 3),
and wild-type (N¼ 3) mutation status, respectively. Patients with
clinical benefit from dacarbazine and dasatinib had significantly
longer OS than those without (51.6 vs 22.3 weeks, Po0.01), and
there was a trend towards worse OS in patient with ocular vs non-
ocular primaries (22.9 vs 40.9 weeks, n.s.). There were no
differences in OS on the basis of gender, age, or metastatic stage,
and there were not enough events in the genotyped patients to
allow calculation of the median OS in all groups.
DISCUSSION
The Src family kinases has critical roles in the process of cancer
invasion (Kim et al, 2009), and preclinical data indicates that Src
inhibition may add to tumour control in advanced malignancies
including melanoma (Eustace et al, 2008; Homsi et al, 2009; Fraser
et al, 2010). In the current study, we show that dasatinib, a Src/abl
kinase inhibitor, can be safely combined with dacarbazine at an
adequate dose intensity. Dose expansion cohorts at three levels
were accrued to profile-delayed toxicities and to get a better
estimate of efficacy. Toxicities were primarily haematological,
and treatment discontinuations were required with post-cycle
1 therapy in patients receiving dasatinib 70mg PO b.i.d with
dacarbazine 1000mgm2 IV every 3 weeks. At this dose level,
objective responses were noted in 2 out of 11 (18.2%) patients and
clinical benefit in 7 out of 11 (54.5%) patients. Treatment was
better tolerated in patients receiving 70mg PO b.i.d with
dacarbazine 800mgm2. Objective tumour responses were
observed in 2 patients (11%), and clinical benefit was observed
in 11 out of 18 patients (61.1%) in this cohort. On the basis of these
findings, the latter dose level would be appropriate for further
clinical trials. In contrast to a recent phase II study of dasatinib
monotherapy (Kluger et al, 2011), grade 3 and 4 pulmonary and
gastrointestinal toxicities were infrequent, occurring in only 2 of
33 patients (6.1%) receiving dasatinib 70mg PO b.i.d. Grade 3
and 4 pleural effusions were not observed. The lower incidence of
these side effects in the present study may be due to the steroid
premedication used with dacarbazine, dacarbazine itself, or the
dasatinib dosing schedule that included a three-day pause in
dasatinib dosing on treatment days 20, 21, and 1. Of note, the first
17 patients treated in the prior study started with dasatinib dosed
at 100mg PO b.i.d, and the majority of these patients required
early treatment interruptions due to treatment-associated toxicity.
The incidence of pulmonary and gastrointestinal toxicity was
markedly lower in patients enrolled subsequently at a dose of
70mg PO b.i.d.
Dasatinib combined with dacarbazine appears to be more active
than either agent alone, with the caveat that cross-trial compar-
isons must be interpreted with extreme caution. In a phase II trial,
dasatinib monotherapy yielded a median PFS of 8 weeks and a 6
month PFS rate of 13% (Kluger et al, 2011). Similarly, patients
treated with dacarbazine alone typically demonstrate objective
disease progression on the first restaging scan (e.g. Chapman et al,
2011). In contrast, the median PFS for patients treated with
dacarbazineþ dasatinib was 13.4 weeks and the 6-month PFS rate
was 20.7%. Furthermore, both the 6-month PFS and 12-month OS
rates for dacarbazine and dasatinib compare favourably with
benchmarks established in the Korn et al (2008) meta-analysis
based on 42 trials, which completed accrual between 1975 and 2005
(6-month PFS¼ 20.7% vs 14.5%, 95% CI 12.9–16.1%; 12-month
OS¼ 34.5% vs 25.5%, 95% CI 23.6–27.4%). These findings suggest
that the addition of dasatinib to dacarbazine may decrease the
dissemination of advanced melanoma lesions, consistent with
reductions in tumour cell invasion and migration induced by
dasatinib in pre-clinical studies (Eustace et al, 2008, 2010).
The current study supports further exploration of BRAF/NRAS/
KIT wild-type status as one of several candidate biomarkers that
could help to identify patients who are most likely to benefit from
dacarbazine with dasatinib. The absence of BRAF and NRAS
mutations in melanoma cell lines is associated with a greater
sensitivity to dasatinib in vitro (Journe et al, 2010). Genotyping
data from the current study were limited by tissue availability and
subject to non-random selection. However, the finding that two of
four clinical responders to dasatinib with dacarbazine did not have
Table 4 Best tumour response by RECIST criteria as a function of
dacarbazine and dasatinib dose
Dacarbazine
(mgm2) Dasatinib
Not
evaluable PD (%) SD (%) PR (%) CR
800 50mg b.i.d. — 2/3 1/3 — —
800 70mg b.i.d. 1 5/18 (27.8) 11/18 (61.1) 2/18 (11.1) —
1000 70mg b.i.d. 3 3/11 (27.3) 6/11 (54.5) 2/11 (18.2) —
1000 140mg daily — 1/3 2/3 — —
1000 100mg daily — 5/11 (45.5) 6/11 (54.5) — —
Abbreviations: CR¼ complete response; PD¼ progressive disease; PR¼ partial
response; RECIST¼Response Evaluation Criteria in Solid Tumours; SD¼ stable
disease. Four patients were not evaluable for response due to adverse events before
the first restaging scans.
†This patient with an NRAS mutation had marked clinical progression at 3 weeks follow-up 
*Progression of non-targets at first restaging 
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Figure 1 (A) Best percent changes in overall RECIST score by treatment
group. *Progression of non-targets. aMarked clinical progression at 3 weeks.
bDasatinib dose (mg) and frequency. cDacarbazine dose (mgm2).
(B) Exploratory analysis: best RECIST response by tumour mutation
status. wThis patient with an NRAS mutation had marked clinical progres-
sion at 3 weeks follow-up. *Progression of non-targets at first restaging.
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the BRAF/NRAS/c-Kit mutations is intriguing and bears further
evaluation in the context of a phase II clinical trial. Additional
candidate biomarkers could also be explored in such a trial
including caveolin-1, an Src substrate that influences c-Src kinase
activity. Caveolin-1 expression in melanoma is associated with
increased cellular proliferation (Felicetti et al, 2009; Trimmer et al,
2010), and in some studies, enhanced tumour cell invasion and
migration (Felicetti et al, 2009). Several studies have identified
elevated caveolin-1 expression as a biomarker of response to
dasatinib in breast, lung, and prostate cancer cells (Finn et al,
2007; Huang et al, 2007; Wang et al, 2007). Furthermore, in a
phase II trial of single-agent dasatinib, five out of six metastatic
melanoma patients with objective tumour-size reductions had
elevated caveolin-1 expression levels before treatment (Jilaveanu
et al, 2011).
Preliminary data suggest that c-Kit inhibitors, including
dasatinib, are highly active in c-Kit mutant melanoma (Lutzky
et al, 2008; Carvajal et al, 2009, 2011; Woodman et al, 2009;
Handolias et al, 2010; Guo et al, 2011), and dasatinib is currently
in phase II testing in patients with solar, mucosal, and acral
melanoma (‘Dasatinib in Advanced Mucosal, Acral, or Solar
Melanoma,’ ClinicalTrials.gov, no date). However, in the current
study, none of the genotyped patients who benefitted clinically
harboured c-Kit mutations.
In summary, the combination of dacarbazine and dasatinib is
well tolerated at clinically relevant dose levels. Dacarbazine dose at
800mgm2 combined with 70-mg dasatinib twice daily warrants
further evaluation in the context of a phase II clinical trial in
advanced melanoma, and this trial could further evaluate
candidate biomarkers for response. These biomarkers, if validated,
may help to identify the optimal target population for treatment
with dacarbazine and dasatinib in combination.
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